Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 27 - Drugs for disorders of the senses
Patents for A61P 27 - Drugs for disorders of the senses (53,017)
10/2000
10/19/2000WO2000061748A1 48 human secreted proteins
10/19/2000WO2000061628A1 49 human secreted proteins
10/19/2000WO2000061625A1 48 human secreted proteins
10/19/2000WO2000061620A1 49 human secreted proteins
10/19/2000WO2000061606A1 Novel human voltage-gated potassium channel
10/19/2000WO2000061596A1 50 human secreted proteins
10/19/2000WO2000061576A1 Triarylimidazoles
10/19/2000WO2000061571A1 4,5-diaryl-3(2h)-furanone derivatives as cyclooxygenase-2 inhibitors
10/19/2000WO2000061542A1 Caspase inhibitors and the use thereof
10/19/2000WO2000061168A1 Ocular treatment using cyclosporin-a derivatives
10/19/2000WO2000061164A1 Modulation of excitable tissue function by peripherally administered erythropoietin
10/19/2000WO2000061148A1 Inhibitors for optic hypofunction caused by optic nerve cell injury induced by factors other than optic circulatory disorder
10/19/2000WO2000061122A2 Use of 6-methylmercaptopurine riboside in ophthalmologic compositions
10/19/2000WO2000034780A3 METHODS AND COMPOSITIONS USEFUL FOR TARGETING ACTIVATED VITRONECTIN RECEPTOR αvβ¿3?
10/19/2000DE19917505A1 Treating cytokine-mediated diseases, e.g. asthma, allergy, eczema, rheumatoid arthritis or transplant rejection, using new or known maduraphthalazine derivatives
10/19/2000DE19916837A1 New di- or tetrahydro-benzoazulene derivatives, are integrin inhibitors useful e.g. for treating thrombosis, coronary heart disease, arteriosclerosis, tumors, osteoporosis or rheumatoid arthritis
10/19/2000CA2383940A1 Modulation of excitable tissue function by peripherally administered erythropoietin
10/19/2000CA2371172A1 50 human secreted proteins
10/19/2000CA2370767A1 49 human secreted proteins
10/19/2000CA2370523A1 49 human secreted proteins
10/19/2000CA2370189A1 48 human secreted proteins
10/19/2000CA2369822A1 Novel human voltage-gated potassium channel
10/19/2000CA2369619A1 Caspase inhibitors and the use thereof
10/19/2000CA2369299A1 Inhibitor of visual function disturbance caused by optic nerve cell disorder due to factor other than ophthalmic circulatory disorder
10/19/2000CA2365917A1 Bone morphogenic proteins
10/19/2000CA2365910A1 Human proteins and polynucleotides encoding them
10/19/2000CA2365905A1 48 human secreted proteins
10/18/2000EP1044967A2 2-Pyridinylguanidine urokinase inhibitors
10/18/2000EP1044678A1 Lacrimal gland specific emulsions for topical application to ocular tissue
10/18/2000EP1044201A1 3-substituted adenines via2-thioxanthines
10/18/2000EP1044001A1 Integrin receptor antagonists
10/18/2000CN1270027A Stable aqueous solution of phthalylglutamic acidimide derivative
10/17/2000US6133309 Treatment of T-helper cell type 2-mediated immune disease by retinoid antagonists
10/17/2000US6133291 3-(piperidin-1-ylalkylene)imidazole derivatives; glaucoma, antiallergens; antiinflammation and hypotensive agents, sleeping disorders; hypermotility of the gastrointestinal tract, alzheimer's disease, schizophrenia and
10/17/2000US6133272 Nitrosated and nitrosylated phosphodiesterase inhibitor compounds, compositions and their uses
10/17/2000US6133267 Use of 2-(2-morpholinophenyl) guanidine derivatives for the treatment of diabetes complications
10/17/2000US6133240 Tetrahydronapthalene derivatives and their therapeutic use
10/17/2000US6133031 Antisense inhibition of focal adhesion kinase expression
10/17/2000US6132759 Medicaments containing gelatin cross-linked with oxidized polysaccharides
10/17/2000CA2305893A1 Use of maduraphthalazine derivatives as inhibitors of proinflammatory cytokines
10/13/2000CA2305047A1 2-pyridinylguanidine urokinase inhibitors
10/12/2000WO2000060051A2 Arpe-19 as a platform cell line for encapsulated cell-based delivery
10/12/2000WO2000059904A2 Compounds and methods to treat cardiac failure and other disorders
10/12/2000WO2000059901A1 Substituted 1,4-dihydroindeno[1,2-c]pyrazoles as inhibitors of tyrosine kinase
10/12/2000WO2000059889A1 α-SUBSTITUTED CARBOXYLIC ACID DERIVATIVES
10/12/2000WO2000059886A2 Benzimidazole abd imidazolophyridine derivaties, their preparation and their use as selective modulators of bradykinin b2 (=bk-2) receptors
10/12/2000WO2000059874A1 NOVEL AMIDE DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEINASES, TNF-α, AND AGGRECANASE
10/12/2000WO2000059520A1 Herbal compositions and uses for the treatment of allergic reactions
10/12/2000WO2000059509A1 Phthalazine derivatives for treating inflammatory diseases
10/12/2000WO2000059503A1 Pyrrolidine modulators of chemokine receptor activity
10/12/2000WO2000059502A1 Pyrrolidine modulators of chemokine receptor activity
10/12/2000WO2000059448A2 Association of no-synthase inhibitor(s) and metabolic antioxidant(s)
10/12/2000WO2000035939A3 Connective tissue growth factor fragments and methods and uses thereof
10/12/2000WO1999064039A9 Bradykinin antagonists
10/12/2000WO1993012754A3 Tertiary and secondary amines as alpha-2 antagonists and serotonin uptake inhibitors
10/12/2000CA2373717A1 Pyrrolidine modulators of chemokine receptor activity
10/12/2000CA2369871A1 .alpha.-substituted carboxylic acid derivatives
10/12/2000CA2369544A1 Aryl and heteroaryl fused aminoalkyl-imidazole derivatives:selective modulators of bradykinin b2 receptors
10/12/2000CA2368686A1 Substituted 1,4-dihydroindeno[1,2-c]pyrazoles as inhibitors of tyrosine kinase
10/12/2000CA2366944A1 Pyrrolidine modulators of chemokine receptor activity
10/12/2000CA2366264A1 Novel amide derivatives as inhibitors of matrix metalloproteinases, tnf-.alpha., and aggrecanase
10/12/2000CA2365834A1 Herbal compositions and uses for the treatment of allergic reactions
10/12/2000CA2365500A1 Association of no-synthase inhibitor(s) and metabolic antioxidant(s)
10/11/2000EP1043365A1 Polymerizable 1,2-dipyrazolylethenes as dyes for ophthalmic plastic lenses
10/11/2000EP1042343A1 Vegi, an inhibitor of angiogenesis and tumor growth
10/11/2000EP1042300A1 Phthalazine derivatives phosphodiesterase 4 inhibitors
10/11/2000EP1042297A1 Carboxyl acid substituted heterocycles as metalloproteinase inhibitors
10/11/2000EP1042290A1 Aromatic sulfone hydroxamic acid metalloprotease inhibitor
10/11/2000EP1042007A2 Aminobiguanides and the use thereof to disinfect contact lenses and preserve pharmaceutical compositions
10/11/2000EP1041993A1 Ophthalmic compositions and process of using
10/11/2000EP1041990A1 Composition for treating respiratory and skin diseases, comprising at least one leukotriene antagonist and at least one antihistamine
10/11/2000EP1041986A1 Pharmaceutically active compound and methods of use
10/11/2000EP0824916B1 Pranoprofen eyedrops containing organic amine
10/11/2000CN1269785A Aromatic C16-C20 substituted tetrahydro prostaglandius useful as EP agonists
10/11/2000CN1269784A Aromatic C16-C20 substituted tetrahydro prostagladins useful as FP agonists
10/11/2000CN1269729A Composition for releiving inflamation and product thereof
10/11/2000CN1269715A Method and composition for treating late allergic reactions and inflammation diseases
10/11/2000CN1269222A Myopia treating medicine
10/10/2000US6130231 Integrin receptor antagonists
10/10/2000CA2147606C Stable extended release oral dosage composition
10/05/2000WO2000058513A1 49 human secreted proteins
10/05/2000WO2000058494A1 50 human secreted proteins
10/05/2000WO2000058473A2 Nucleic acids including open reading frames encoding polypeptides; 'orfx'
10/05/2000WO2000058467A1 50 human secreted proteins
10/05/2000WO2000058356A1 50 human secreted proteins
10/05/2000WO2000058355A1 50 human secreted proteins
10/05/2000WO2000058350A1 49 human secreted proteins
10/05/2000WO2000058339A2 50 human secreted proteins
10/05/2000WO2000058335A1 47 human secreted proteins
10/05/2000WO2000058334A1 50 human secreted proteins
10/05/2000WO2000058307A2 Aryl fused 2,4-disubstituted pyridines: nk3 receptor ligands
10/05/2000WO2000058295A2 Compounds and methods for treatment of asthma, allergy and inflammatory disorders
10/05/2000WO2000057920A2 Method for expressing proteins
10/05/2000WO2000057914A1 Ocular tension-lowering agents
10/05/2000WO2000057901A1 Modulation of vascular permeability by means of tie2 receptor activators
10/05/2000WO2000057877A1 Aryl substituted pyrazoles, imidazoles, oxazoles, thiazoles and pyrroles, and the use thereof
10/05/2000WO2000057866A2 Use of azalide antibiotics for the topical treatment or prevention of ocular infections
10/05/2000WO2000032228A3 Peptide-based vaccine for influenza
10/05/2000WO2000032178A3 Use of siburamine for the treatment of disorders of the central nervous system secondary to organic impairments
10/05/2000WO2000031280A3 Use of plus-strand synthesis elements in retroviral vectors
1 ... 433 434 435 436 437 438 439 440 441 442 443 444 445 446 447 448 449 450 451 452 453 ... 531